WZ811 is a highly potent competitive antagonist of CXCR4. WZ811 shows subnanomolar potency (EC50 = 0.3 nM) in an affinity binding assay. WZ811 inhibits CXCR4/stromal cell-derived factor-1 (SDF-1)-mediated modulation of cyclic adenosine monophophate (cAMP) levels (EC50 = 1.2 nM). In addition, WZ811 efficiently inhibits SDF-1 induced Matrigel invasion (EC50 = 5.2 nM).
|Source||PLoS One (2017). Figure 2. WZ 811|
|Cell Lines||U87.CD4.CXCR4 cells|
|Results||100 μMof CTCE-9908, WZ811 and Me6TREN did not affect the calcium flux evoked by CXCL12 (IC50s >100,000 nM)|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 30 mg/mL|
Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.
Zhu A, et al. J Med Chem. 2010 Dec 23;53(24):8556-68. PMID: 21105715.
Discovery of small molecule CXCR4 antagonists.
Zhan W, et al. J Med Chem. 2007 Nov 15;50(23):5655-64. PMID: 17958344.
|Related CXCR Products|
LY2510924 is a potent and selective CXCR4 antagonist, which blocks SDF-1 binding to CXCR4 with IC50 of 0.079 nM.
Motixafortide (BL-8040) is an antagonist of CXCR4 with IC50 value of 1 nM.
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4).
SX-682 is a potent and selective CXCR1/2 allosteric inhibitor, it may be useful for castration-resistant prostate cancer.
VUF11207 fumarate is a CXCR7 agonist and a high-potency CXCR7 ligand (pKi=8.1).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.